TLC Submits IND Application In Taiwan For TLC19 Inhalable Liposomal Hydroxychloroquine For COVID-19

Taiwanese specialty pharmaceutical company Taiwan Liposome Co. Ltd. (TLC) announced Friday the submission of an Investigational New Drug (IND) Application to the Taiwan Food and Drug Administration (TFDA) for TLC19 Hydroxychloroquine Liposome Inhalation Suspension for the treatment of coronavirus (COVID-19) disease.

from RTT - Biotech https://ift.tt/31ToNM6
via IFTTT